SOPHiA GENETICS™

in partnership with PARAGON GENOMICS

# Accelerating Global SARS-CoV-2 Research and Surveillance

## Highlights

- SARS-CoV-2 whole genome analyses to identify new and circulating strains*:
  - ✓ 'UK' (B.1.1.7)
  - ✓ 'South African' (B.1.351)
  - ✓ 'Brazilian' (P.1)
  - ✓ 'South. Californ.' (B.1.429)
  - ✓ 'New York' (B.1.526)
- Accurate genotyping for high quality data
- Streamlined approach for efficient analyses

Leveraging on SOPHiA GENETICS' extensive experience and knowledge in genomics, Paragon Genomics SARS-CoV-2 Panels powered by SOPHiA DDM™ generate high quality whole viral genome analyses with next generation sequencing for tracking and surveillance.


## End-to-end Workflow: from Sample to Report

### Scalable Library Preparation and Target Enrichment

- >99% coverage of whole SARS-CoV-2 genome*

### Easy Data Upload and Management

- Unlimited, secured cloud-based storage
- Built-in quality indicators

### Advanced Analytics

- Detection of Indels with high analytical sensitivity
- 2.5% more false-positive mutations filtered out*
- Integrated, secured access to community-level data

### Customized Virus Presence Report

- Automatic clade and lineage information
- Comprehensive sampling data and metadata

*Results may vary. Data on file*

# Identify New and Emerging Variants

Our recent analyses show the overall clade distribution in SOPHiA DDM™ is similar to the global datasets available, that require manual upload and analyses.

With the SOPHiA DDM™ platform, not only is the quality of data controlled, but analyses can be automated, and data can be screened in real time.

Paragon Genomics SARS-CoV-2 Panels powered by SOPHiA DDM™ enables high-quality genotyping that is indispensable for error-free evolution studies. As the number of users increase, so does the opportunity to accelerate global research and surveillance efforts.

**Want to know more?**

**Contact us >**




# Make the Most of your Clinical Samples

**Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples**




To help improve global research efforts, our genomic experts at SOPHiA GENETICS have worked with international partners to offer new guidelines to optimize the quality and confidence in amplicon-based SARS-CoV-2 genotyping.

The broadly applicable and easy-to-implement guidelines should greatly contribute to increase the quality of reported SARS-CoV-2 genotypes. Overall, this will help ensure both the analytical accuracy and reliability in the data that will lead to future breakthroughs in managing COVID-19.

**Want to learn how to make the most of your clinical samples?**

**Read guidelines now >**

## ABOUT US

SOPHiA GENETICS is a health company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new generation health data for cancer and rare diseases management, SOPHiA allows clinical researchers to act with precision and confidence as well as biopharma to optimize their entire drug-development process. The company's innovative approach enables an ever-expanding community of over 1,000 institutions to benefit from knowledge sharing, thus fostering a new era in healthcare. SOPHiA's achievement is recognized by the MIT Technology Review's "50 Smartest Companies".